Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Telix Pharmaceuticals's TLX-101?
TLX-101 is a small molecule commercialized by Telix Pharmaceuticals, with a leading Phase II program in Glioblastoma Multiforme (GBM). According...
Data Insights
Risk adjusted net present value: What is the current valuation of Telix Pharmaceuticals's TLX-101?
TLX-101 is a small molecule commercialized by Telix Pharmaceuticals, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM)....